Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
← catalyst calendarNCT07427394 · readout in 497 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
24estimated
Sites
6
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-06 | actual | When the study began enrolling |
| Primary completion | 2027-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Breast Cancer
Interventions
- Drug: Camizestrant
- Drug: Atirmociclib
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious AEs
measured Up to Post-Treatment Follow up (Day 30 Post Dose)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed